Sant Cugat del Valles 11 January 2015. Hospital General de Catalunya, part of the Quirónsalud group, and the Dr. Rosell Oncology Institute (IOR) have signed a strategic agreement to provide precision oncology and personalized cancer treatment. IOR is to provide quality services in the areas of cancer patient care, including management of outpatient facilities and clinical trials, within the Hospital General, located in Sant Cugat dels Valles, Barcelona.

This partnership with the Hospital General de Catalunya, led by oncologist Dr Rafael Rosell, a world leader in oncology, brings the experience of an internationally recognized team to the benefit of cancer patients. This joining forces of two leaders in health service provision and oncology places the best of precision medicine and personalized cancer treatment at the disposal of patients.



With this agreement, the Hospital General adopts the IOR model of comprehensive cancer treatment with an innovative strategy: personalized therapy models based on genetic analyses. Each tumor has its own genetic fingerprint and its determination permits treatment to be tailored to each patient. IOR comprises a team of medical oncologists specialized in different types of cancer that place their extensive experience at the service of each patient.



A differential factor is that IOR has its own Molecular Oncology Laboratory which works closely with the oncologists to offer personalized treatments based on genetic characteristics of each patient’s tumor. As the team includes highly-skilled and specialized technical staff, biologists and pathologists, the quality, speed and accuracy of results is guaranteed.



Dr. Xavier Mate, Director of the Hospital General de Catalunya believes that this alliance "is important with regard to our strategy to have the best professionals in the field of oncology and improve the care of cancer patients. This intiative is something that benefits both our patients, our partners and all our professionals." The agreement is strategic for IOR since it allows them to place all its capabilities in the fields of molecular diagnostics, clinical trials and oncology at the service of patients.



About Dr Rafael Rosell

The IOR team is led by Dr Rafael Rosell, MD, PhD, founder of the Spanish Lung Cancer Group, President and Scientific Director of Pangaea, and Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology (ICO). Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition: in 2013 he was recognized by The Lancet as the highest authority in lung cancer in Europe, and he has received numerous awards in recognition of his tireless investigations into the causes and treatment of cancer.



About the Dr Rosell Oncology Institute

The Dr Rosell Oncology Institute offers comprehensive, personalized anti-cancer treatment based on genetic analyses of each patient’s tumor. The service is led by internationally renowned oncologist Dr Rafael Rosell with a team of medical oncologists specialized in different types of cancer. The clinic is served by a state-of-the-art Molecular Oncology Laboratory that works closely with doctors to provide rapid, accurate genetic testing. Results are used to select the most appropriate treatment for each patient, therefore maximizing therapeutic benefit and efficacy.



About Quirónsalud

Quirónsalud is the leading health service provider in Spain. It is a young brand, the result of a merger between IDCsalud and Quirón, but boasts over 60 years experience in the health care sector. Quirónsalud covers all medical specialties to provide comprehensive patient care. It has more than 70 centers throughout Spain, a prestigious professional team, advanced technology, a valuable research and teaching vocation, and a management model based on a strong commitment to quality.